B cell characteristics and total numbers predict SARS-CoV-2 vaccination response among patients treated with rituximab

Authors :: Stefanski, Ana-Luisa
Rincon-Arevalo, Hector
Schrezenmeier, Eva
Karberg, Kirsten
Szelinski, Franziska
Ritter, Jacob
Schrezenmeier, Hubert
Chen, Yidan
Burmester, Gerd-Rüdiger
Lino, Andreia C.
Dörner, Thomas
Publication Year :: 2022
Publisher :: German Medical Science GMS Publishing House, 2022.
Abstract: Introduction: Patients with autoimmune inflammatory rheumatic diseases (AIRD) receiving rituximab (RTX) therapy are at higher risk for poor COVID-19 outcomes [ref:1] and show substantially impaired anti-SARS-CoV-2 vaccine responses [ref:2]. Thus, the ability to further define and [for full text, please go to the a.m. URL]

Full Text Access

Tools